Covalon TechnologiesCVALF -1.79%83 Cyclically Adjusted PB Ratio is 2.65 as of Jul. 09, 2026, which is 16% below its 10-year median of 3.14. GuruFocus rates CVALF with a GF Score™ of 83/100 and a GF Value™ of $1.53 (Fairly Valued). The stock has 2 warning signs investors should review. Among 524 Medical Devices & Instruments companies, Covalon Technologies ranks worse than 62.79% on this metric.
The historical rank and industry rank for Covalon Technologies's Cyclically Adjusted PB Ratio or its related term are showing as below:
CVALF'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.03 Med: 3.14 Max: 11.02
Current: 2.64
During the past years, Covalon Technologies's highest Cyclically Adjusted PB Ratio was 11.02. The lowest was 1.03. And the median was 3.14.
CVALF's Cyclically Adjusted PB Ratio is ranked worse than 62.79% of 524
companies
in the Medical Devices & Instruments industry
Industry Median: 1.785
vs CVALF: 2.64
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Covalon Technologies's adjusted book value per share data for the three months ended in Mar. 2026 was $0.739. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.57 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Covalon Technologies (OTCPK:CVALF) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Covalon Technologies Cyclically Adjusted PB Ratio Related Terms
Covalon Technologies Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Covalon Technologies's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Covalon Technologies Cyclically Adjusted PB Ratio Chart
CVALF vs ISRG, BDX, MDLN: Cyclically Adjusted PB Ratio Comparison
For the Medical Instruments & Supplies subindustry, Covalon Technologies's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Covalon Technologies Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Covalon Technologies's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Covalon Technologies's Cyclically Adjusted PB Ratio falls into.
Covalon Technologies Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 2.65 mean?
Covalon Technologies (CVALF) has a Cyclically Adjusted PB Ratio of 2.65 as of Jul. 09, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Covalon Technologies and its competitors. This is 16% below median its historical median of 3.14. Over the past decade, Covalon Technologies' Cyclically Adjusted PB Ratio has ranged from 1.03 to 11.02. According to the industry distribution chart, Covalon Technologies ranks #329 out of 524 companies in the Medical Devices & Instruments industry, placing it in the top 62.8%.
Is Covalon Technologies' Cyclically Adjusted PB Ratio too high?
Covalon Technologies' current Cyclically Adjusted PB Ratio of 2.65 is 16% below median its 10-year median of 3.14. Over the past 10 years, this metric has ranged from a low of 1.03 to a high of 11.02. The Medical Devices & Instruments industry median Cyclically Adjusted PB Ratio is 1.79. Covalon Technologies' value of 2.65 is 48.5% above this industry median. Based on the distribution chart, Covalon Technologies ranks #329 out of 524 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Covalon Technologies has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Covalon Technologies' Cyclically Adjusted PB Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Covalon Technologies ranks #329 out of 524 companies for Cyclically Adjusted PB Ratio. This places Covalon Technologies in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.79. Covalon Technologies' value of 2.65 is 48.5% above this benchmark. Historically, Covalon Technologies' own Cyclically Adjusted PB Ratio has ranged from 1.03 to 11.02 over the past decade. While the company's 10-year median is 3.14 vs. the industry median of 1.79, Covalon Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PB Ratio among Medical Devices & Instruments companies is 1.79, based on 524 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Covalon Technologies's current Cyclically Adjusted PB Ratio of 2.65 is 48.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Covalon Technologies and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PB Ratio is 1.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Covalon Technologies's current Cyclically Adjusted PB Ratio is 2.65, which is 16% below median its own 10-year median of 3.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Covalon Technologies stock overvalued right now?
Based on GuruFocus' analysis, Covalon Technologies (CVALF) is currently considered Fairly Valued. The stock's GF Value™ is $1.53, compared to a current price of $1.51 — trading 1.3% below its estimated fair value. The current Cyclically Adjusted PB Ratio is 2.65, which is 16% below median its 10-year median of 3.14 and 48.5% above the Medical Devices & Instruments industry median of 1.79. Covalon Technologies' overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Covalon Technologies (CVALF), the current Cyclically Adjusted PB Ratio is 2.65 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Covalon Technologies (CVALF) Overvalued in 2026?
Based on GuruFocus' analysis, Covalon Technologies stock appears to be undervalued.
The current stock price of $1.51 is trading 1.3% below its estimated GF Value™ of $1.53.
GuruFocus considers Covalon Technologies to be Fairly Valued.
Key valuation signals for CVALF:
Cyclically Adjusted PB Ratio: 2.65 (16% below median its 10-year median of 3.14)
GF Value™: $1.53 vs. price of $1.51 (1.3% below fair value)
Industry Position: 48.5% above the Medical Devices & Instruments median (#329 of 524)
No single metric tells the full story. See the CVALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Covalon Technologies Ltd is engaged in the business of researching, developing, manufacturing, and marketing patent-protected medical products that improve patient outcomes in the areas of infection management, wound care, and surgical procedures. The company generates revenue through development contracts, licensing agreements, distribution contracts, and sales. Its products include IV dressings, surgical site protection products, vascular access protection products, and others, and its solutions include primary dressing cover, vascular access technologies, advanced wound care, sensitive skin solutions, custom medical coatings, and patient resource support.
83GF Score
Get the complete analysis for CVALF
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVALF has been successfully added to your 
